IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options.
IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.

Biotechnology

Life Sciences

Therapeutics

Isomab Ltd

Isomab Ltd's headquarters in Nottingham, United Kingdom

Description

People (3)

Dr Kishor Modha

Jay Modha

Anker Lundemose

Jobs